Quick Answer
Cardiff Oncology, Inc. reported Net Income of -$45.85 million for fiscal year 2025.
Cardiff Oncology, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$45.85M | -0.9% |
| 2024 | -$45.43M | -9.6% |
| 2023 | -$41.44M | -7.1% |
| 2022 | -$38.70M | -36.8% |
| 2021 | -$28.29M | -46.5% |
| 2020 | -$19.31M | -17.6% |
| 2019 | -$16.41M | +0.3% |
| 2018 | -$16.46M | +33.9% |
| 2017 | -$24.91M | +36.5% |
| 2016 | -$39.20M | -42.7% |
| 2015 | -$27.47M | -91.8% |
| 2014 | -$14.33M | -21.3% |
| 2013 | -$11.81M | -2.1% |
| 2012 | -$11.57M | -416.5% |
| 2011 | -$2.24M | +58.9% |
| 2010 | -$5.45M | -119.4% |
| 2009 | -$2.48M | +51.9% |
| 2008 | -$5.17M | -10.3% |
| 2007 | -$4.68M | +34.4% |
| 2007 | -$7.13M | +9.1% |
| 2006 | -$7.84M | -46.0% |
| 2005 | -$5.37M | -1302.3% |
| 2004 | -$383.0K | +20.5% |
| 2003 | -$481.6K | +8.1% |
| 2002 | -$524.2K | -95.9% |
| 2001 | -$267.6K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.26M | +5.0% | +19.3% |
| June 30, 2025 | -$13.94M | -18.4% | -3.8% |
| March 31, 2025 | -$13.43M | -34.2% | -13.3% |
| September 30, 2024 | -$11.86M | -21.8% | -0.7% |
| June 30, 2024 | -$11.78M | -5.6% | -17.7% |
| March 31, 2024 | -$10.01M | +10.8% | -2.9% |
| September 30, 2023 | -$9.73M | -13.5% | +12.7% |
| June 30, 2023 | -$11.15M | -6.8% | +0.7% |
- Cardiff Oncology, Inc. showed a decrease of -0.9% in Net Income compared to the prior fiscal year.
- Over the 2001–2025 period, Cardiff Oncology, Inc.’s net income has declined by 17034.2% (from -$267.6 thousand to -$45.85 million).
- The most recent figure is from Cardiff Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: